by nikki mann | Dec 7, 2022 | News
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3. STORM Therapeutics is a clinical stage biotechnology company creating...
by nikki mann | Nov 29, 2022 | News
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the company’s investment in a new Discovery Centre in London, located in the heart of the Knowledge Quarter. MSD scientists in...
by nikki mann | Nov 23, 2022 | News
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering wider cross-sector collaboration. Colleagues from affiliated academic institutes have participated in our annual...
by nikki mann | Nov 16, 2022 | News
We are delighted that Dr Manav Pathania and team, who are based at the Milner Therapeutics Institute, have been awarded ~£1 million from Cancer Research UK, to investigate paediatric high-grade gliomas. These rare brain tumours account for less than 20% of brain...
by nikki mann | Oct 20, 2022 | News
In May 2021, the Milner Institute launched a rapid response data analysis call, led by Dr Rebecca Harris. The call sought collaborative project proposals from CRUK Cambridge Centre researchers and clinicians with multiomic oncology data sets that would benefit from...
by nikki mann | Oct 7, 2022 | News
We were delighted to receive an award at the Vice-Chancellor’s Awards for Research, Impact and Engagement last week. Milner Directors Tony Kouzarides and Kathryn Chapman were presented with the runners-up trophy for collaboration at an awards ceremony held at...
